Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Government confirms findings from ICMR and NCDC studies that COVID-19 vaccines do not cause sudden deaths; experts highlight genetic and lifestyle factors as main contributors.

No link between vaccines and sudden deaths in India post COVID, studies find

Government confirms findings from ICMR and NCDC studies that COVID-19 vaccines do not cause sudden deaths; experts highlight genetic and lifestyle factors as main contributors.

In the wake of Karnataka Chief Minister Siddaramaiah linking heart-related deaths in Hassan district to Covid vaccine, the Union Health Ministry on Wednesday said extensive studies by ICMR and AIIMS have conclusively established no linkages between coronavirus vaccines and sudden deaths.
Siddaramaiah had on Tuesday said "hasty approval and distribution" of the Covid vaccine to the public could also be a reason for these deaths.
He urged everyone to visit the nearest health centre immediately for a check-up if they have symptoms such as chest pain or difficulty breathing, and not to ignore these signs.
The ministry said the matter of sudden unexplained deaths has been investigated through several agencies in the country and these studies have conclusively established that there is no direct link between COVID-19 vaccination and reports of sudden deaths.
Studies by the Indian Council of Medical Research (ICMR) and National Centre for Disease Control (NCDC) affirm that COVID-19 vaccines in India are safe and effective, with extremely rare instances of serious side effects, it said.
Sudden cardiac deaths can result from a wide range of factors, including genetics, lifestyle, pre-existing conditions, and post-Covid complications, the ministry said in a statement.
The ICMR and NCDC have been working together to understand the causes behind sudden unexplained deaths, especially in young adults between the ages of 18 and 45 years.
To explore this, two complementary studies were undertaken using different research approaches -- one based on past data and another involving real-time investigation.
The first study conducted by ICMR's National Institute of Epidemiology (NIE) was titled "Factors associated with unexplained sudden deaths among adults aged 18-45 years in India - a multi-centric matched case control study." This study was carried out from May to August 2023 across 47 tertiary care hospitals in 19 states and Union territories, the statement said.
It looked at individuals who appeared to be healthy but died suddenly between October 2021 and March 2023.
The findings have conclusively showed that COVID-19 vaccination does not increase the risk of unexplained sudden deaths in young adults.
The second study titled "Establishing the cause in sudden unexplained deaths in young" is currently being conducted by the All India Institute of Medical Sciences (AIIMS), New Delhi with funding and in collaboration with ICMR.
This is a prospective study aimed at determining the common causes of sudden deaths in young adults. Early analysis of data from the study indicates that heart attacks or myocardial infarction (MI) continue to be the leading cause of sudden death in this age group, the statement said.
Importantly, no major changes in the pattern of causes have been observed when compared with previous years. In majority of the unexplained death cases, genetic mutations have been identified as a possible cause of these deaths. The final results will be shared once the study is complete.
Together, these two studies offer a more comprehensive understanding of sudden unexplained deaths in young adults in India.
It has also been found that COVID-19 vaccination does not appear to increase the risk, whereas, the role of underlying health issues, genetic predisposition and risky lifestyle choices does play a role in unexplained sudden deaths, the statement said.
"Scientific experts have reiterated that statements linking Covid vaccination to sudden deaths are false and misleading, and are not supported by scientific consensus," the statement said.
Speculative claims without conclusive evidence risk undermining public confidence in vaccines, which have played a crucial role in saving millions of lives during the pandemic, it said.
Such unfounded reports and claims could strongly contribute to vaccine hesitancy in the country, thereby adversely impacting public health.
The government remains committed to evidence-based public health research to protect the well-being of its citizens, the statement said.
The Karnataka chief minister had said more than 20 people have died due to heart attacks in the past month alone in just one district of Hassan.
"The government is taking this matter very seriously. To identify the exact cause of these series of deaths and to find solutions, a committee of experts has been formed under the leadership of Dr Ravindranath, Director of Jayadeva Institute of Cardiovascular Sciences and Research, and they have been instructed to submit a study report within 10 days," he said in a post on X.

Maharashtra reports 34 new COVID-19 cases and one fatality, increasing the year's total to 2,041 cases with 29 deaths. The state continues to manage 512 active cases.

Maharashtra Records 34 New COVID-19 Cases, One Fatality

Maharashtra sees 34 new COVID-19 cases, with one recent death, tallying 2,041 cases and 29 fatalities this year. This emphasizes the need for vigilance against COVID-19.

Maharashtra reports 34 new COVID-19 cases and one death, raising the state's total to 2,041 cases and 29 deaths this year. The recent fatality involved a woman with chronic liver cirrhosis in Mumbai. Currently, 512 cases are active.

Maharashtra on Monday reported 34 new COVID-19 cases, while one fatality was recorded in the last 24 hours, a health department official said.
The tally in the state since January 1 this year stands at 2041, while the death toll is 29, including 28 with comorbidities.
There are 512 active cases in the state.
A 44-year-old woman died in the metropolis, the official said, adding she was suffering from chronic liver cirrhosis, which is considered a comorbidity.
The new cases include 12 from Mumbai, eight from Pune and seven from Chhatrapati Sambhajinagar, the state health department said.
Since January 1, a total of 21,951 COVID-19 tests have been carried out, it said.

Nagaland reports its first COVID-19 case of the year in Dimapur. The patient, with mild symptoms, is in home isolation. Health officials stress calm and adherence to preventive measures.

Nagaland Confirms First COVID-19 Case of the Year in Dimapur

Nagaland confirms its first COVID-19 case of 2023 in Dimapur. The patient has mild symptoms and is in home isolation. Authorities urge the public to stay calm and follow COVID-appropriate behaviors to prevent spread.

Nagaland reports first COVID-19 case in Dimapur, with mild symptoms. Health officials stress need for continued vigilance and adherence to COVID-appropriate behavior to prevent spread.

Nagaland on Monday reported the first COVID-19 case of the year with a resident of Dimapur testing positive, a statement said.
The patient is mildly symptomatic and is currently under home isolation, being closely monitored by health authorities, said the statement issued by Director of Health and Family Welfare Mereninla Senlem.
The current variants of COVID-19 are mild, having symptoms such as fever, cough, and sore throat, which typically subside without the need for hospitalisation, it said.
The government advised the people not to panic and continue following COVID-appropriate behaviour to prevent the spread of the virus.

Karnataka CM Siddaramaiah launches an investigation into high COVID-19 test charges by private hospitals, emphasizing collaboration for effective pandemic management.

Karnataka CM Investigates COVID-19 Test Costs

Karnataka CM Siddaramaiah prompts a probe into high charges by private hospitals for COVID-19 testing. With rising cases, the focus is on improved management and department collaboration.

Karnataka CM Siddaramaiah calls for a probe into private hospitals' COVID-19 testing charges amid a review meeting about rising cases and management clarity.

Karnataka Chief Minister (CM) Siddaramaiah said on Wednesday that private hospitals imposing exorbitant charges unnecessarily in the name of COVID-19 testing must be investigated.
The CM chaired a meeting to discuss the COVID-19 situation in Karnataka.
Health department officials informed the CM that in the last 10 days, 5,000 tests were conducted in the test, revealing 862 COVID-positive cases, stated a press release issued by the Chief Minister&rsquo;s Office.
So far, 11 deaths have been registered in the state, but COVID-19 was not the cause of death in 10 of these cases, the press release added.
Officials also informed the CM that an audit report is awaited for one case, said the press release.
The CM also instructed officials to avoid unnecessary confusion and to ensure that all hospitals have appropriate systems in place to manage COVID-19 cases, according to the press release.
He also insisted on inter-department coordination. The Health Department and the Medical Education Department must work in coordination, CM is quoted as saying in the press release.
Health Minister Dinesh Gundu Rao, Chief Minister&rsquo;s Political Secretary Nasir Ahmed, Chief Secretary to the Government Shalini Rajneesh, and Chief Minister's Additional Chief Secretary Anjum Parwez were also present during the meeting.

A 90-year-old woman in Delhi succumbed to multiple health conditions, having tested positive for COVID-19. Her death marks the eighth fatality related to COVID-19 since January 1. Delhi, with 691 active cases, is closely monitoring the situation.

90-Year-Old Dies with COVID-19 in Delhi

In Delhi, a 90-year-old woman with numerous health issues has died after testing positive for COVID-19, marking the eighth related death since the start of the year. Health conditions rather than the virus were primarily responsible. Nationwide, active cases total 6,815.

90 Year Old Dies with COVID-19 in Delhi

A 90-year-old woman in Delhi died from pre-existing conditions while having COVID-19. Delhi sees 691 active cases, part of India's 6,815 nationwide. Kerala, Gujarat, West Bengal, and Delhi are highly affected.

A 90-year-old woman with co-morbidities died after testing positive for COVID-19 in the national capital, according to official data.
The number of fatalities since January 1 stands at eight. The 90-year-old patient had respiratory acidosis, Congestive Heart Failure (CCF) and Chronic Kidney Disease (CKD), according to the Union Health Ministry's COVID-19 dashboard.
The primary cause of death is other co-morbidities and Covid finding is incidental, it said.
Delhi has 691 active cases. Active cases across India stand at 6,815, with three deaths reported in the past 24 hours.
Kerala continues to be the most affected state, followed by Gujarat, West Bengal and Delhi, the ministry data show.

Odisha reports seven new COVID-19 cases, bringing total infections to 30. Health officials recommend caution during the Rath Yatra festival and schools will require masks and isolation for symptomatic students starting June 20.

Odisha Records New COVID-19 Cases; Advisory Issued

Odisha reports seven new COVID-19 cases, totaling 30 in this wave. Health advisory urges symptomatic individuals to avoid Rath Yatra. Schools will enforce precautionary measures post-summer, maintaining vigilance despite a low positivity rate.

Odisha reports seven new COVID-19 cases, with total infections now at 30. Health officials urge caution ahead of the Rath Yatra festival, recommending digital viewing for symptomatic individuals. Schools to implement measures post-summer break.

Seven more people tested positive for COVID-19 in Odisha, taking the total number of infections in the current wave to 30, a senior health officer said on Friday.
State public health director Nilakantha Mishra said seven have recovered from the disease so far.
The total number of active cases currently stood at 23, and no one is serious, he said.
&ldquo;On average, five to seven new cases are being detected every day. We are holding discussions with officers concerned at the Centre for issuance of an advisory to the people,&rdquo; Mishra said.
State health services director Amarendra Nath Mohanty has advised people with COVID-19 symptoms not to visit Puri during the upcoming Rath Yatra later this month.
Such persons can witness the festival through television and other media platforms, he said.
&ldquo;At present, we are testing samples of those who have been hospitalised, and the test positivity rate remains at 1 or 1.5 per cent, which is low. However, we all have to remain cautious.&rdquo; On Thursday, the state government had hinted that preventive measures could be taken in schools when the institutes reopen on June 20 after summer vacation.
School and Mass Education Minister Nityananda Gond had said that students with COVID-like symptoms would be asked to wear masks in schools, while those with more acute signs of the infection would be asked to stay home and isolate themselves, he said.

India’s active Covid-19 cases have crossed 5,000, with Kerala reporting the highest numbers, followed by Gujarat, West Bengal, and Delhi. The Centre is conducting mock drills to ensure healthcare facilities are prepared.

India's active COVID-19 caseload cross 5,000; Kerala most affected state

India&rsquo;s active Covid-19 cases have crossed 5,000, with Kerala reporting the highest numbers, followed by Gujarat, West Bengal, and Delhi. The Centre is conducting mock drills to ensure healthcare facilities are prepared.

India's active Covid case tally crossed the 5,000 mark with Kerala remaining the most affected state followed by Gujarat, West Bengal and Delhi, according to the Union Health Ministry data released on Friday.
In view of the increase in cases, the Centre is conducting mock drills to check facility-level preparedness for COVID-19.
All states have been instructed to ensure availability of oxygen, isolation beds, ventilators, and essential medicines in view of rising cases of Covid.
There are 5,364 active cases in India and four fresh deaths have been reported in the last 24 hours.
Official sources have maintained that most cases are mild and managed under home care.
Since January this year, 55 deaths have been reported in the country. There were a total of 257 active patients in the country on May 22.
A series of technical review meetings were held on June 2 and 3 under chairpersonship of Dr Sunita Sharma, Director General of Health Services (DGHS) with representatives of Disaster Management Cell, Emergency Management Response (EMR) Cell, National Centre for Disease Control (NCDC), Indian Council of Medical Research (ICMR), Integrated Disease Surveillance Programme (IDSP) and Central Government Hospitals in Delhi and with representatives from all states and UTs to evaluate the current COVID-19 situation and preparedness measures.
Official sources on June 4 said that State and District surveillance units under IDSP are closely monitoring Influenza Like Illness (ILI) and Severe Acute Respiratory Illness (SARI).
"Testing is recommended for all admitted SARI cases and 5 per cent of ILI cases as per guidelines and positive SARI samples are sent for Whole Genome Sequencing through the ICMR VRDL network," an official source had said.&nbsp;

Delhi faces increased COVID-19 cases as a 22-year-old woman becomes the fifth fatality this year. Health Ministry calls for improved healthcare.

Delhis Fifth COVID-19 Death in 2025

Amidst rising COVID-19 cases, Delhi reports its fifth death this year, with the Health Ministry urging states to enhance infrastructure.

Delhi records fifth COVID-19 death this year, highlighting rising cases. The Health Ministry stresses improved healthcare infrastructure.

A 22-year-old woman suffering from bilateral respiratory tract infection and pulmonary tuberculosis succumbed after testing positive for COVID-19 - the fifth fatality due to the infection in the national capital this year, according to the Union Health Ministry.
Delhi has seen an uptick in coronavirus infections, with 457 active cases at present.
The woman had a history of pulmonary tuberculosis, bilateral lower respiratory tract infection, COVID pneumonia, and Type 1 Respiratory failure, according to the ministry.
The government website did not say whether the woman was a city resident or was admitted to any health facility here.
India's active COVID cases stand at 4,302, with Kerala remaining the most affected state, followed by Maharashtra, Gujarat, and Delhi, according to the Union Health Ministry COVID-19 dashboard.
Of the four fatalities reported in the last fortnight, two were elderly, while two were younger women with a history of pulmonary tuberculosis.
All states have been instructed to ensure availability of oxygen, isolation beds, ventilators and essential medicines in view of rising cases of COVID, an official source said on Wednesday.

Sikkim records 15 new COVID-19 cases. Masks and sanitizer use now mandatory in state medical facilities. Hospitals prepared with COVID-19 dedicates setups. Public advised to follow safety guidelines. Awareness camps planned.

Sikkim COVID-19 Update: 15 New Cases, Safety Measures Enforced

Since May 29, Sikkim reported 15 COVID-19 cases after testing 526 samples. Safety measures include mandatory masks and sanitizers in state medical facilities. The state is equipped with dedicated COVID-19 setups and plans public awareness camps.

Health minister confirms 15 COVID cases in Sikkim

Sikkim reports 15 COVID-19 cases since May 29, out of 526 tests. Mask-wearing and sanitizer use are mandatory. Hospitals are equipped for cases.

Sikkim has reported 15 COVID-19 cases since May 29, state Health minister G T Dhungel said on Wednesday.
He said 526 samples were tested since May 29, of which 15 tested positive for COVID-19 at STNM Hospital, Gangtok.
The Health minister said that wearing masks and use of sanitisers has been made mandatory along with following COVID protocols in all state-run medical facilities in the state.
Dhungel said that all hospitals and health centres in the state have already established separate COVID facilities with adequate beds, oxygen cylinders and medical equipment. He also that specialised manpower to deal with COVID cases has also been constituted.
The minister asked the people of the state that there was no need to panic and to follow COVID-19 protocols.
"Prevention is better than cure and we urge all citizens to remain safe by following the laid down guidelines by the Centre and state agencies. We can tackle this communicable and contagious disease with awareness," he said.
The minister also said that the Health department will immediately start organising COVID awareness camps throughout the state.

The CDC reports NB.1.8.1, a new COVID-19 variant, at U.S. airports, linked to surging infections in Asia. It's detected in multiple states, with current vaccines offering protection.

New COVID Variant Detected at U.S. Airports

The NB.1.8.1 variant from Asia has been detected at U.S. airports. Found in several states, it's linked to surges in China, with vaccines still protective.

The CDC reports NB.1.8.1, a new COVID-19 variant, at U.S. airports

The new COVID-19 variant NB.1.8.1 detected in U.S. airports links to China's surge. Found in several states; vaccines remain effective.

New COVID-19 Variant Detected at U.S. Airports Amid Global Surge
The Centers for Disease Control and Prevention (CDC) has reported the detection of a new COVID-19 variant, linked to a significant surge of infections in China, at several U.S. airports. The variant, identified as NB.1.8.1, has been found in foreign travelers arriving at airports in Washington state, California, the New York City area, and Virginia, according to a recent report by CBS News.
Data from the Global Initiative on Sharing All Influenza Data (GISAID) indicates that many of these cases are linked to travelers from countries like Japan, South Korea, France, and China. The airport screening program conducted these tests between April 22 and May 12.
Beyond the airport detections, cases of the NB.1.8.1 variant have been identified in other U.S. states, including Ohio, Rhode Island, and Hawaii, representing separate clusters, as per the CBS report.
U.S. health authorities are maintaining vigilance over this variant, which is currently dominant in China and experiencing a rise in cases across parts of Asia, notably Hong Kong, where infections have reached the highest levels in over a year.
Preliminary studies suggest that NB.1.8.1, part of the JN.1 group of variants, may have higher transmissibility than previous variants. However, it does not appear to cause more severe illness, and existing vaccines are believed to offer protection against it.
Current Situation in the U.S.
The CDC has acknowledged the presence of NB.1.8.1 cases in the U.S. but notes that fewer than 20 sequences of the variant have surfaced in their baseline surveillance data, preventing its inclusion in the COVID Data Tracker dashboard. Officials have stated that they continue to monitor all SARS-CoV-2 sequences closely, adding that if the variant's prevalence increases, it will be added to the dashboard.
Simultaneously, U.S. authorities are also scrutinizing the XFC variant, which has shown significant growth domestically. Despite the U.S. experiencing a relatively predictable pattern of biannual surges in COVID-19 cases&mdash;typically during the summer and winter&mdash;experts caution that the virus's evolution remains unpredictable.
COVID-19 Fatalities Persist
While infections have seen a decline, COVID-19 continues to claim an average of 350 American lives per week, according to CDC data. Although this figure is markedly lower than the peak of 25,974 deaths in the week ending January 9, 2021, it underscores ongoing challenges. Health experts attribute persistent high death rates to factors such as low vaccination rates, waning immunity, and insufficient access to treatments.
As the situation evolves, health authorities stress the importance of vaccination, vigilance, and international cooperation in curbing the spread of new COVID-19 variants.

After Covishield, now research and reports suggest that Covid-19 vaccine Covaxin also has side effects. Here is all we know.

Covid-19 vaccination: Study finds Covaxin vaccine has adverse side effects. All you need to know

<h2>After Covishield, now research and reports suggest that Covid-19 vaccine Covaxin also has side effects. Here is all we know.</h2>

After Covishield, now research and reports suggest that Covid-19 vaccine Covaxin also has side effects. This report comes weeks after Covishield maker AstraZeneca accepted that their vaccine may have rare side effects. Now, a recent study has highlighted the side effects of Bharat Biotech's Covaxin with nearly a third of the participants reported experiencing adverse events of special interest (AESI) following vaccination. Read on to know more.
<h3>Covaxin users report adverse side effects</h3>
According to a report by Times Now, a new study has found that adolescent females and those with a history of allergy are at a higher risk of adverse events of special interest or AESI after receiving Covaxin. They cited a report on SpringerLink, an integrated platform for journals and other materials published by Springer. Springer is the observational research conducted by Banaras Hindu University. They have written in their report that about one-third of the population jabbed with Covaxin has reported AESI.
The Economic Times reported that of 1,024 individuals enrolled, 635 adolescents and 291 adults could be contacted during the year-long follow-up. The study revealed that at least 47.9 per cent of adolscents and 42.6 per cent of adults reported viral upper respiratory tract infections.
<h3>What is AESI?</h3>
According to experts, AESI is a defined condition that occurs in some people following immunization, with the potential to be causally associated with a vaccine product.
AESI include anaphylaxis, myocarditis, and thrombosis with thrombocytopenia syndrome, characterized by blood clots and low levels of platelets.
Also watch: <a href="https://www.editorji.com/lifestyle-news/health/new-variant-flirt-in-india-infectious-disease-expert-shares-effects-and-precautions-1715760293964">New variant FLiRT in India: Infectious Disease expert shares effects and precautions</a> &nbsp;

A new variant of Covid 19 is causing havoc in the US. Here is all you need to know about the new variant FLiRT.

New Covid-19 variant FLiRT reason to worry? Here is all you need to know

<h2>A new variant of Covid 19 is causing havoc in the US. Here is all you need to know about the new variant FLiRT.</h2>

A new variant of Covid 19 has taken over US. The new variant FLiRT belongs to the Omicron's JN.1 lineage. With new mutations, the variants KP.2 and KP 1.1 are considered to be more infectious than previous Omicron variants. However, the main symptoms remain more or less the same. Until now the KP.2 variant has spread faster than the KP.1.1 variant.
The nickname 'FLiRT" is based on the technical names for their mutations, according to the Infectious Disease Society of America. Here is all you need to know about the latest Covid variant.
<h3>FLiRT variant takes over US, all you need to know</h3>
According to a report by Hindustan Times, FLiRT are the descendants of the JN. 1 variant that came in last December. They carry some fresh mutations that help them spread easily. It has emerged from the Omicron JN.1 lineage and are rapidly spreading across the U.S.
The most prominent FLiRT variant is KP.2 which is accounting for around 25% of new COVID-19 cases as of April 2024. 
Some main symptoms of the new variant are sore throat, cough, fatigue, nasal congestion, runny nose, headache, muscle aches, fever, and potential loss of taste or smell. These symptoms are similar to the Omicron variant.
To be safe from the variant, make sure to continue using a mask, maintain social distancing and take influenza shots. Elderly and the immuno-compromised should be more careful.
While it has not spread in India yet, the potential spread of these variants is a significant concern given the country's high population density.
Also watch: <a href="https://www.editorji.com/lifestyle-news/health/h5n1-flu-100-times-more-dangerous-than-covid-19-warns-researchers-here-is-what-expert-says-1712378314503">H5N1 flu '100 times' more dangerous than Covid-19, warns researchers. Here is what expert says</a> &nbsp;

AstraZeneca has said that its vaccine against COVID-19, which was made under licence in India as Covishield, could cause low platelet counts and formation of blood clots in "very rare" cases.

Covishield row: Parents to sue SII alleging vaccine caused daughter's death

Parents to sue SII alleging Covishield caused daughter's death

AstraZeneca has said that its vaccine against COVID-19, which was made under licence in India as Covishield, could cause low platelet counts and formation of blood clots in "very rare" cases.

Parents of a girl who died after taking Covishield, an Indian variant of AstraZeneca's Covid-19 vaccine, have decided to move the Supreme Court against the Serum Institute of India (SII). SII, the Pune-based firm, developed and manufactured Covishield in the country.
This comes days after the vaccine manufacturer AstraZeneca admitted that the vaccine can cause a rare side effect TTS (Thrombosis with Thrombocytopenia Syndrome).
As per an India Today report, the victim, Karunya, died in July 2021 after taking a Covishield shot. &nbsp;However, the national committee set up by the Union government reported that there is insufficient evidence to link the death of the girl to the vaccine.
The case, however, came to the limelight after AstraZeneca, a British-Swedish firm, admitted the side effects of the vaccine in response to a lawsuit in a UK court.
Hindustan Times reported the father of the victim Venugopalan Govindan will move a writ petition to the court seeking compensation and the appointment of an independent medical board to inquire into his daughter's death.
Govindan said that the admission by the AstraZeneca comes too late and after many lives were already lost.&nbsp;
He said "A few months after the vaccine was administered, in March 2021, 15 European countries suspended or age-limited the vaccine after deaths or blood clots cases were reported. AstraZeneca and Serum Institute of India should have stopped vaccine manufacturing."
Govindan has made it his mission to file more cases if sufficient remedies were not taken from the present case. "We will file more cases against the perpetrators who are responsible for the deaths of our children."
On May 1, a plea was filed in the Supreme Court on Wednesday seeking constitution of a medical expert panel under the supervision of a retired apex court judge to examine any possible side effects and risk factors of the Covishield vaccine.
It claimed that UK-headquartered pharmaceutical company AstraZeneca has said that its vaccine against COVID-19, which was made under licence in India as Covishield, could cause low platelet counts and formation of blood clots in "very rare" cases.
The application, filed by advocate Vishal Tiwari, also sought a direction to the Centre to compensate those who are severely disabled or have died because of any side effects of the vaccine administered to them during Covid.

Karnataka health minister Dinesh Gundu Rao on January 5 said that Covid test has been made mandatory for those showing symptoms of Influenza Like Illness or Severe Acute Respiratory Illness. 

Covid test mandatory in Karnataka for patients with respiratory and flu-like illnesses

Karnataka health minister Dinesh Gundu Rao on January 5 said that Covid test has been made mandatory for those showing symptoms of Influenza Like Illness or Severe Acute Respiratory Illness.

Karnataka Health Minister Dinesh Gundu Rao on Friday said he has directed health officials to make Covid test mandatory for those with Influenza Like Illness (ILI) or Severe Acute Respiratory Illness (SARI).
The minister also said that a Covid helpline will be launched tomorrow.
&ldquo;More than 7,000 tests are being done everyday and the COVID Positivity Rate is 3.82 per cent. The positivity rate in the state has not come down yet,&rdquo; the minister said in a statement after a meeting with health department officials here.
Stating that neighbouring Kerala has started seeing a downward trend in Covid cases, he said he has asked officials to keep a close watch on those who are Covid positive.
Rao said he has asked officials to compulsorily carry out Covid screening among those adults showing symptoms of ILI and SARI.
Earlier only one in 20 of these cases were subjected to Covid testing but henceforth private and government hospitals have been instructed to conduct the test on all ILI/SARI patients.
&ldquo;Those with symptoms are being monitored and tested. Those who are in isolation at home have been told to take extra care. It is expected that the trend of decreasing Covid cases may start next week in Karnataka. Technical Advisory Committee met yesterday (Thursday) and gave some guidance. I have instructed the authorities to adopt them (the guidelines),&rdquo; Rao said.&nbsp;

A new variant of Covid, the JN.1 variant is not a new reason for concern, according to Dr Venkat Ramesh, Infectious Disease Physician. Read the exclusive interview here!

Covid JN.1 variant: Is the new virus a cause to panic? Expert reveals

A new variant of Covid, the JN.1 variant is not a new reason for concern, according to Dr Venkat Ramesh, Infectious Disease Physician. Read the exclusive interview here!

A new variant of covid has created havoc across the world. JN.1 variant has also made its way to India and many have been affected by the virus. More than 100 cases of the new covid variant have been detected in many states including Kerala and Delhi.
Is the new variant a cause for alarm and what is the best way to not transmit it? We at Editorji spoke to Dr Venkat Ramesh, Infectious Disease Physician, regarding its characteristics and transmissibility. The doctor also revealed if the virus is a cause to panic.
<h3>Is there a cause for panic?</h3>
Dr Venkat Ramesh revealed that there is no need to worry and precautions is the best way to ensure you stay safe. He told us, "As of now, there is really no need to be panicked or alarmed, we need to be cautious and vigilant. But certainly do not need to panic. The month of January will give us some clarity in terms of which direction we are headed. As infectious disease physicians, we have not seen an increase in the number of cases due to covid in our hospitals in case of patients being admitted with covid."
He further added, Another thing I would like to emphasise is that the three doses of vaccine may not provide gove great protection against infection with this new variant but it will definitely protect against serious infection, severe disease, ICU admission, and death. So will past infections also. So in that sense, as a country and society we are well protected."
Also watch: <a href="https://www.editorji.com/lifestyle-news/health/covid-jn-1-variant-is-a-booster-dose-necessary-as-cases-rise-across-india-expert-weighs-in-1704014949197">Covid-19 JN.1 variant: Do you need booster shots to fight surge? Expert weighs in</a> &nbsp;

With over 100 cases of covid JN.1 in India, Dr Venkat Ramesh, Infectious Disease Physician tells us if a booster dose is necessary and what are the precautions one must take. Read on!

Covid-19 JN.1 variant: Do you need booster shots to fight surge? Expert weighs in

With over 100 cases of covid JN.1 in India, Dr Venkat Ramesh, Infectious Disease Physician tells us if a booster dose is necessary and what are the precautions one must take. Read on!

Almost four years ago we realised the dangers of Covid-19. As we step into 2024, covid's new variant JN.1 has been circulating in India. While the first case was detected in Kerala, More than 100 JN.1 cases have been registered in India (until today) and the numbers are sharply on the rise.&nbsp;
The new variant of Covid-19, the JN.1 variant is a new source of concern amongst Indians. We at Editorji spoke to Dr Venkat Ramesh, Infectious Disease Physician, regarding its characteristics and transmissibility. The doctor also spoke to us about the need of a booster dose and what precuations one should take to avoid getting covid.
<h3>Is a booster dose necessary?</h3>
Speaking to us, Dr Venkat Ramesh revealed that anyone and everyone who is eligible to get a booster dose should definitely get it. He said, "What we as a society need to do, in my opinion, are two things: one is that those who are eligible for the third dose or the booster dose, or the so-called precaution dose for the vaccine and haven't taken it should do so because this is mandated by the ministry of health and welfare of India. Second those people who are in a high-risk group should engage in a covid appropriate behaviour and perhaps to a certain extent all of us. But definitely, those people who are in a high-risk group or more prone to severe covid should mask up, avoid crowded places, avoid areas with poor ventilation, indoor environments and so on."
Make sure to use mask and sanitise your hands regularly.
Also watch: <a href="https://www.editorji.com/lifestyle-news/health/covid-19-jn-1-variant-symptoms-and-how-to-distinguish-from-regular-cold-1703938697404">Covid-19 JN.1 variant: Symptoms and how to distinguish from regular cold</a> &nbsp;

India recorded 841 new cases of Covid-19, highest since May, on December 30. Three fatalities in 24 hours. 

Covid-19: 841 new cases reported in India, highest since May  

Covid-19 update: India recorded 841 new cases of Covid-19, highest since May, on December 30. Three fatalities in 24 hours. 

India recorded 841 new cases of Covid-19, highest since May, on December 30. Three fatalities in 24 hours.&nbsp;

India has logged 841 new cases of COVID-19, the highest in 227 days, while the number of active cases of the infection have been recorded at 4,309, the health ministry said on Sunday.
Three new fatalities due to Covid- one each from Kerala, Karnataka and Bihar -- have been reported in a span of 24 hours, according to the ministry's data updated at 8 am.
India had recorded 865 new cases on May 19.
The number of daily cases had dropped to double-digits till December 5, but cases have again gone up after emergence of a new variant and cold weather conditions.
The daily numbers were in lakhs at the peak of the pandemic, which began in early 2020 and has seen more than 4.5 crore people getting infected and over 5.3 lakh deaths in about four years since then across the country.
The number of people who have recuperated from the disease stands at over 4.4 crore with a national recovery rate of 98.81 per cent, according to the ministry's website.
According to the website, 220.67 crore doses of Covid vaccines have so far been administered in the country.

Delhi reports first case of Covid JN. 1 sub variant

In Delhi, a 28-year-old man, who had comorbidities, died, with Covid not being the primary reason.

Amid a surge in Covid-19 cases in the country, national capital New Delhi has reported first case of sub-variant JN.1.&nbsp; 
Delhi has more than 35 active cases with nine fresh infections being reported on Wednesday, an official said, adding that a 28-year-old man, who had comorbidities, died, with Covid not being the primary reason.
"The man was not from Delhi and was referred to a private hospital recently. He had multiple comorbidities and the Covid finding was incidental. The sample of the man has been sent for genome sequencing and a report is awaited," he added.
The official said multiple samples were sent for genome sequencing, and one of them tested positive for the JN.1 variant.
India recorded 529 fresh COVID-19 cases in a single day, while the country's active infection count stood at 4,093, the health ministry said on Wednesday.
Three new fatalities -- two from Karnataka and one from Gujarat -- were reported in a span of 24 hours, according to the ministry's data updated at 8 am.
The number of daily cases had dropped to double-digits till December 5, but infections have again gone up after emergence of a new variant and cold weather conditions.

India witnesses a surge in Covid-19 cases which are being linked to its sub-variant JN.1. Ex-WHO scientist Dr. Soumya Swaminathan emphasizes preparedness, urging use of masks, staying home in case of flu symptoms, and vigilance to curb spread.

JN.1 Covid 19: As cases surge, know what precautions to take while traveling this winter season

<div class="flex-1 overflow-hidden">
<div class="react-scroll-to-bottom--css-ghhwp-79elbk h-full">
<div class="react-scroll-to-bottom--css-ghhwp-1n7m0yu">
<div class="flex flex-col pb-9 text-sm">
<div class="w-full text-token-text-primary" data-testid="conversation-turn-35">
<div class="px-4 py-2 justify-center text-base md:gap-6 m-auto">
<div class="flex flex-1 text-base mx-auto gap-3 md:px-5 lg:px-1 xl:px-5 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem] group final-completion">
<div class="relative flex w-full flex-col lg:w-[calc(100%-115px)] agent-turn">
<div class="flex-col gap-1 md:gap-3">
<div class="flex flex-grow flex-col max-w-full">
<div class="min-h-[20px] text-message flex flex-col items-start gap-3 whitespace-pre-wrap break-words [.text-message+&amp;]:mt-5 overflow-x-auto" data-message-author-role="assistant" data-message-id="4286fd22-5a50-4e2e-bfaa-77363ff73834">
<div class="markdown prose w-full break-words dark:prose-invert light">
India witnesses a surge in Covid-19 cases which are being linked to its sub-variant JN.1. Ex-WHO scientist Dr. Soumya Swaminathan emphasizes preparedness, urging use of masks, staying home in case of flu symptoms, and vigilance to curb spread.
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>

Cases of Covid 19's sub variant JN.1 has been rapidly increasing in India due to the festivities and holiday season. If you too are planning to travel during this festive season, you must take precautions and stay safe.
<h3>Precautions</h3>
Preventive measures encompass regular hand sanitization, the utilization of triple masks, and adherence to social distancing. Additionally, individuals may contemplate receiving booster shots to enhance their protection against the virus.
<h3>All about the COVID-19 new variant</h3>
The new variant is known as Covid JN.1. This variant is a descendant of the previous strain BA.2.86 or Pirola. The case was first detected in the US in September this year and then later seven cases were found in China. Even though BA.2.86 and JN.1 sound very different because of the way variants are named, the only difference between them is of a spike protein.
<h3>What are the symptoms?</h3>
Some common symptoms of the new variant of Covid-19 are fever, runny nose, headache, and sore throat. Other symptoms are mild upper respiratory problems, which typically improve within four or five days.&nbsp;
However, there is no need to panic as the symptoms are similar to viral flu, and with precautions you can avoid catching the new variant of Covid-19. According to a doctor who spoke to ANI, there will not be a new wave of Covid-19, "I don't think I would be wise enough to say that the new wave of COVID is coming. It may just pass away like any other viral infection. Let's keep a watch and keep our fingers crossed."
Also watch: <a href="https://www.editorji.com/lifestyle-news/health/all-you-need-to-know-about-covid-19-new-variant-jn-1-symptoms-prevention-tips-and-more-1702882355534">All you need to know about Covid-19 new variant JN.1.: Symptoms, prevention tips and more</a>

2 people have died and 20 more Covid cases have been registered in Karnataka. As per the report, the deaths were reported on December 16 and 17, however, the variant of the virus was not disclosed.

2 Covid related deaths reported in Karnataka: 20 more people affected

2 people have died and 20 more Covid cases have been registered in Karnataka. As per the report, the deaths were reported on December 16 and 17, however, the variant of the virus was not disclosed.

Two Covid-19 related deaths and 20 fresh cases were reported in Karnataka, according to a Health bulletin issued on Wednesday. The bulletin stated that the deceased - both male aged 44 and 76 - died on December 16 and December 17 respectively in Bengaluru. One of them was asymptomatic while the other patient complained of breathlessness. Earlier in the day, Karnataka Health Minister Dinesh Gundu Rao said that a 64-year-old man died in the city due to Covid-19 infection five days ago. Asked if the cause of death was the new subvariant JN.1 of the SARS CoV-2 virus, he said it was not known so far. The person, who had comorbidities, was a resident of Chamarajpet and died on December 15, the Minister told reporters. In the last 24 hours, a total of 808 tests were done across various districts in the state, out of which 407 were RT-PCR and 401 were Rapid Antigen Tests. The covid positivity rate in the state stood at 2.49 per cent while the case fatality rate stood at 10 per cent, it stated. As of Wednesday, there are 92 active cases in Karnataka, of which, 72 are in home isolation, 20 in hospital, seven in ICU and 13 in general ward, it added. Rao, meanwhile, said the state government would increase testing to gauge the rate of Covid-19 infections. In the next three days, it intends to increase the number to 5,000 tests per day. RT-PCR tests have been made mandatory for all severe acute respiratory infection (SARI) cases, and at least 1 in 20 influenza-like illness (ILI) cases, he said. A meeting will be held with Chief Minister Siddaramaiah and the Technical Advisory Committee (TAC) on Thursday to discuss further measures to be taken and preparations made, Rao said.
Also watch: <a href="https://www.editorji.com/india-news/21-cases-of-covid-sub-variant-jn-1-found-in-three-states-1703075206732">21 cases of Covid sub-variant JN.1 found in three states</a> He said there is need to do more tests and genome sequencing to know about the spread of infection, adding, instructions have been issued to do more tests, especially in border districts -- Dakshina Kannada, Kodagu, Chamarajanagara and Mysuru. The Karnataka government on Tuesday issued an advisory asking people above 60 years, those with comorbidities, pregnant women and lactating mothers, to wear face masks when outdoor, and to strictly avoid visiting closed, poorly ventilated spaces and crowded areas, in the wake of current Covid-19 situation in the country and detection of JN.1 sub-variant in neighbouring Kerala.

covid 19

Categories